2-39023128-C-G
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PS1PM2PM5PP3_StrongPP5_Very_Strong
The NM_005633.4(SOS1):c.1300G>C(p.Gly434Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Pathogenicin Lovd. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G434K) has been classified as Likely pathogenic.
Frequency
Consequence
NM_005633.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SOS1 | NM_005633.4 | c.1300G>C | p.Gly434Arg | missense_variant | 10/23 | ENST00000402219.8 | NP_005624.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SOS1 | ENST00000402219.8 | c.1300G>C | p.Gly434Arg | missense_variant | 10/23 | 1 | NM_005633.4 | ENSP00000384675.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 29, 2019 | The SOS1 c.1300G>C; p.Gly434Arg variant has been described in individuals with Noonan syndrome (NS; Koh 2019, Roberts 2007). It is absent from general population databases (Exome Variant Server and Genome Aggregation Database), indicating it is not a common polymorphism. Functional analyses of the p.Gly434Arg variant demonstrate increased activation over wildtype, consistent with other NS-causing variants (Smith 2013). Additionally, another variant that results in the same amino acid change at this codon (c.1300G>A; p.Gly434Arg) has been described in at least one individual affected with NS (Zenker 2007). Based on available information, the c.1300G>C variant is considered pathogenic. REFERENCES Koh A et al. The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome. Mol Genet Genomic Med. 2019 Apr; 7(4): e00581. Roberts A et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007 Jan;39(1):70-4. Smith M et al. NMR-based functional profiling of RASopathies and oncogenic RAS mutations. Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4574-9. Zenker M et al. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet. 2007 Oct;44(10):651-6. - |
Noonan syndrome 4 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | - | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | May 05, 2019 | PS2, PS3, PS4_moderate, PM1, PM2, PP3 - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 27, 2024 | The p.G434R pathogenic mutation (also known as c.1300G>C), located in coding exon 10 of the SOS1 gene, results from a G to C substitution at nucleotide position 1300. The glycine at codon 434 is replaced by arginine, an amino acid with dissimilar properties. This variant was reported in multiple individuals with features consistent with Noonan syndrome, including a de novo occurrence (Roberts AE et al. Nat Genet, 2007 Jan;39:70-4; Pierpont EI et al. Am J Med Genet A, 2010 Mar;152A:591-600; Lepri F et al. Hum Mutat, 2011 Jul;32:760-72; Koh AL et al. Mol Genet Genomic Med, 2019 Apr;7:e00581). A different alteration located at the same position, resulting in the same protein change, c.1300G>A (p.G434R), has been detected in individuals with Noonan syndrome (Zenker M et al. J Med Genet, 2007 Oct;44:651-6; Alfieri P et al. Am J Med Genet A, 2014 Apr;164A:934-42; Chinton J et al. Arch Argent Pediatr, 2019 10;117:330-337). In an assay testing SOS1 function, this variant showed a functionally abnormal result (Smith MJ et al. Proc Natl Acad Sci U S A, 2013 Mar;110:4574-9). In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. - |
Fibromatosis, gingival, 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Aug 23, 2021 | - - |
RASopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 21, 2020 | This variant has been reported to have conflicting or insufficient data to determine the effect on SOS1 protein function (PMID: 23487764). For these reasons, this variant has been classified as Pathogenic. This variant has been observed in individuals and families affected with clinical features of Noonan syndrome, in at least one of whom it was found de novo (PMID: 17143285, 20186801, 17586837, 21387466, 30784236). This sequence change replaces glycine with arginine at codon 434 of the SOS1 protein (p.Gly434Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. This variant is not present in population databases (ExAC no frequency). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at